OBJECTIVE: To define and characterize responders and non-responders in a group of 124 @entity1 with @entity11165 who received a single treatment with intravenous immunoglobulin. DESIGN: Open trial, prospective follow-up study. METHODS: Clinical examination and data from medical records. Short Form 36 (SF-36), Physical Activity Scale for the Elderly (PASE) and visual analogue scale (VAS) measured quality of life, physical activity and intensity of @entity158 , respectively. Data were obtained before treatment and at 6-month follow-up. RESULTS: Two responder groups were identified with the outcome SF-36 Vitality and 3 with @entity158 , respectively. Forty-five percent were positive-responders, identified before treatment by reduced physical function, @entity2057 in the lower extremities, higher levels of @entity1295 and @entity158 , and a @entity227 score above 20. Negative-responders were identified by good physical function and mental health, lesser @entity2057 in the lower extremities, and low levels of @entity1295 and @entity158 . CONCLUSION: Intravenous immunoglobulin is a biological intervention, and therefore it is important to be able to identify responders and non-responders. In order to maximize a positive outcome it is suggested that @entity1 with a high level of @entity158 and reduced physical function are selected.

Immunoglobulin treatment in XXXX : Identification of responders and non-responders.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity227 :: ('MESH:D014786', 'Disease') :: ['VAS pain'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity158 :: ('MESH:D010146', 'Disease') :: ['fatigue and/or pain', 'pain', 'Bodily pain'] @entity2057 :: ('MESH:D009133', 'Disease') :: ['muscle atrophy'] @entity11165 :: ('MESH:D016262', 'Disease') :: ['post-polio syndrome']
@entity11165 :: (MESH:D016262,Disease) :: ['post-polio syndrome']
